Feedback

Browsing by M

Use an asterisk (*) for partial word searches (e.g. pemph*)

175 results found.

1.
2.
3.
4.
5.
6.
Ordering Recommendation:   May be useful in the assessment of tissue stores. For routine assessment of magnesium deficiency, Magnesium, Plasma or Serum (0020039) is preferred.
7.
8.
Ordering Recommendation:   Retrospectively diagnose malaria in patients from non-endemic areas with relevant exposure and prior symptoms.
9.
Ordering Recommendation:   Not a first-line test for malaria screening. Refer to parasite smear (0049025) or malaria rapid screen and Giemsa stain (2001547) for screening and diagnosing acute disease.
10.
Ordering Recommendation:   Screen for malaria. Travel history required.
11.
12.
Ordering Recommendation:   Useful as a reasonable indicator of recent, active exposure and provides a modest indicator for distinguishing exposed from non-exposed individuals. May be useful in long-term, low-dose manganese exposure. Whole blood measurements (0099272) are recommended for monitoring potential accumulation with TPN.
13.
Ordering Recommendation:   May be useful as a reasonable indicator of recent, active exposure and provides a modest indicator for distinguishing exposed from nonexposed individuals. Not recommended for the assessment of manganese body stores. Whole blood measurements (0099272) are recommended for monitoring potential accumulation with TPN.
14.
Ordering Recommendation:   Limited utility in determining manganese exposure. Whole blood measurements (0099272) are recommended for determining recent, active exposure.
15.
Ordering Recommendation:   Useful as a reasonable indicator of recent, active exposure and provides a modest indicator for distinguishing exposed from nonexposed individuals. Recommended for monitoring potential accumulation with TPN. Not recommended for detecting long-term, low-dose manganese exposure, refer to Manganese, RBC (2007254).
16.
Ordering Recommendation:   Initial screening for suspected deficiency in the lectin complement pathway.
17.
18.
19.
Ordering Recommendation:   This is a second tier test and REQUIRES PERMISSION from ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.
20.
Ordering Recommendation:   Preferred molecular test if diagnosis of Marfan syndrome is strongly suggested using consensus criteria.
21.
Ordering Recommendation:   Acceptable molecular test for individuals with clinical phenotype of Marfan Syndrome but does not detect deletions or duplications.
22.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
23.
Ordering Recommendation:   Screening test for DS, T18, and ONTD. Risks determined using a combination of 1st and 2nd trimester serum markers, with a 1st trimester NT measurement. Risks provided after both 1st and 2nd trimester specimens are received.
24.
Ordering Recommendation:   Second part of a 2-part test. Requires that the first part (Maternal Screening, Sequential, Specimen #1 0081293) was submitted in the first trimester. Screening test for DS, T18, and ONTD. Risks determined using a combination of 1st and 2nd trimester serum markers, with a 1st trimester NT measurement. Risks provided after both 1st and 2nd trimester specimens are received.
25.
Ordering Recommendation:   Order this test for PREGNANT FEMALE patients only.  For males or non-pregnant females, refer to Alpha Fetoprotein, Serum (Tumor Marker)  (0080428).
26.
27.
Ordering Recommendation:   Second trimester screening test for DS, T18, and ONTD.
28.
Ordering Recommendation:   First trimester screening test for DS and T18. Does not include AFP for ONTD screening. Requires NT measurement performed by an ultrasonographer certified by FMF or NTQR.
29.
Ordering Recommendation:   Screening test for DS, T18, and ONTD. Risks determined using a combination of 1st and 2nd trimester serum markers, with or without 1st trimester nuchal translucency (NT) measurement. Results require a second sample between 15 and 24 weeks gestation (Maternal Serum Screening, Integrated, Specimen #2 0081064).
30.
Ordering Recommendation:   Second part of a 2-part test. Requires that the first part (Maternal Serum Screening, Integrated, Specimen #1 0081062) was submitted in the first trimester. Screening test for DS, T18, and ONTD. Risks determined using a combination of 1st and 2nd trimester serum markers, with or without 1st trimester nuchal translucency (NT) measurement.
31.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
32.
Ordering Recommendation:   Aids in the differential diagnosis of lipomatous neoplasms. The presence of MDM2 amplification supports a diagnosis of well-differentiated liposarcoma / atypical lipomatous tumor, but it is not specific for these diagnoses.
33.
34.
35.
36.
37.
38.
39.
Ordering Recommendation:   Preferred initial molecular (DNA) test to confirm a diagnosis or identify carriers of Medium Chain Dehydrogenase (MCAD) deficiency following clinical and/or biochemical presentation. To diagnose or rule out MCAD deficiency, refer to Acylcarnitine Quantitative Profile, Plasma (0040033), Acylglycine, Quantitative, Urine (0081170), and Organic Acids, Urine (0098389).
40.
Ordering Recommendation:   Molecular (DNA) test to confirm a diagnosis of Medium Chain Dehydrogenase (MCAD) deficiency following clinical and/or biochemical presentation. Recommended when Medium Chain Acyl-CoA Dehydrogenase (ACADM) 2 Mutations (0051205) does not identify two causative mutations. To diagnose or rule out MCAD deficiency, refer to Acylcarnitine Quantitative Profile, Plasma (0040033), Acylglycine, Quantitative, Urine (0081170), and Organic Acids, Urine (0098389).
41.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
42.
43.
44.
45.
46.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
47.
Ordering Recommendation:   Confirm suspected hereditary melanoma cancer syndrome in individuals with personal or family history of melanoma.
48.
49.
Ordering Recommendation:   Monitor patient adherence.
50.
Ordering Recommendation:   Preferred test to follow-up presumptive results. For general screening, Meperidine Urine Screen with Reflex to Quantitation (2012288) is preferred.
51.
Ordering Recommendation:   Useful for general screening in contexts of compliance and/or abuse. A screen with reflex testing is the preferred method for ruling out meperidine exposure. For follow-up testing of a presumptive result, Meperidine, Urine Screen with Reflex to Quantitative (2002760) is preferred.
52.
53.
Ordering Recommendation:   Optimize drug therapy and monitor patient adherence.
54.
55.
56.
Ordering Recommendation:   May be useful in the assessment of acute or chronic elemental or inorganic mercury exposure and/or in monitoring chelation therapy. For the assessment of acute exposure, Mercury, Whole Blood (0099305) is preferred.
57.
Ordering Recommendation:   Preferred test for the assessment of acute mercury exposure. For chronic exposure, Mercury, Urine (0025050) is preferred.
58.
Ordering Recommendation:   Aids in prognostication and therapeutic decisions for neoplasms where amplification has been demonstrated.
59.
Ordering Recommendation:   NOT a first line test for Pompe disease. May be used to confirm diagnosis of metabolic storage disorder in an individual with clinical and biochemical phenotype.
60.
Ordering Recommendation:   Metal ion testing of joint fluid may be complementary to serum testing but is not recommended. Preferred tests for evaluating metal ion release from metal-on-metal joint arthroplasty are Chromium, Serum (0098830) and/or Cobalt, Serum (0025037).
61.
Ordering Recommendation:   First-line test in suspected pheochromocytoma.
62.
Ordering Recommendation:   First-line test in suspected pheochromocytoma.
63.
Ordering Recommendation:   Evaluate if etiology of hypoglycemia is from exposure to metformin. Serum or plasma is the preferred specimen for correlating drug use with hypoglycemia. Order Metformin, Serum or Plasma (0092390).
64.
Ordering Recommendation:   Preferred test when determining if hypoglycemia is from exposure to metformin. Serum or plasma is the preferred specimen for correlating drug use with hypoglycemia.
65.
Ordering Recommendation:   Monitor patient adherence.
66.
Ordering Recommendation:   Preferred test to follow-up presumptive results. For general screening, Methadone Urine Screen with Reflex to Quantitation (2012245) is preferred.
67.
Ordering Recommendation:   Useful for general screening in contexts of compliance and/or abuse. A screen with reflex testing is the preferred method for ruling out methadone exposure. For follow-up testing of a presumptive result, Methadone and Metabolite, Urine Quantitative (0090362) is preferred.
68.
69.
Ordering Recommendation:   Monitor exposure to methanol.
70.
71.
72.
Ordering Recommendation:   Confirm cases of heterozygous or homozygous methemoglobin reductase deficiency.
73.
74.
Ordering Recommendation:   Optimize drug therapy and monitor patient adherence.
75.
Ordering Recommendation:   May be useful in the assessment of Methylenedioxypyrovalerone (MDPV) exposure up to several days post-exposure.
76.
Ordering Recommendation:   Do not use for neural tube defect risk assessment or for thrombophilia screening. Use to determine genetic cause for hyperhomocysteinemia.
77.
78.
Ordering Recommendation:   This test is used to evaluate and monitor methylmalonic acidemia.
79.
80.
Ordering Recommendation:   Monitor patient adherence.
81.
Ordering Recommendation:   Useful for general testing in contexts of compliance and/or abuse. Preferred test to follow-up presumptive results.
82.
83.
84.
Ordering Recommendation:   Optimize drug therapy and monitor patient adherence.
85.
Ordering Recommendation:   Aids in therapeutic decisions in individuals with gliomas.
86.
Ordering Recommendation:   Detect early kidney disease in those with diabetes or other risk factors (eg, hypertension).
87.
Ordering Recommendation:   First-line screening test for Lynch syndrome. Directs additional molecular diagnostic testing for Lynch syndrome.
88.
Ordering Recommendation:   Preferred test to diagnose Microsporidia in immunocompromised patients with persistent diarrhea if Encephalitozoon spp (E. intestinalis/E. hellem/E. cuniculi) or E. bieneusi is the suspected infectious agent.
89.
Ordering Recommendation:   Can be used for follow-up of negative PCR result when suspicion of less common microsporidia are suspected.
90.
Ordering Recommendation:   First-line screening test for Lynch syndrome. Directs additional molecular diagnostic testing for Lynch syndrome.
91.
Ordering Recommendation:   Preferred screening test for Lynch syndrome in individuals with colorectal cancer.
92.
Ordering Recommendation:   Preferred reflex screening test for Lynch syndrome in non-colorectal cancer tumors (eg, endometrial carcinoma) .
93.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
94.
Ordering Recommendation:   Diagnose mitochondrial disorders resulting from mutations in nuclear genes.
95.
Ordering Recommendation:   Assess for nuclear gene mutations causing mitochondrial disease.
96.
Ordering Recommendation:   This is a second tier test and REQUIRES PERMISSION from  ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.
97.
Ordering Recommendation:   Assess for sequence variants in the mitochondrial genome (mtDNA) causing mitochondrial disorders.
98.
Ordering Recommendation:   Diagnose mitochondrial disorders caused by mutations within the mitochondrial genome (mtDNA).
99.
Ordering Recommendation:   Comprehensive genetic test for diagnosing mitochondrial disorders caused by mitochondrial (mtDNA) or nuclear gene mutations.
100.
101.
Ordering Recommendation:   Optimize drug therapy.
102.
Ordering Recommendation:   Distinguishes between Lynch syndrome and sporadic tumors with loss of MLH1.
103.
Ordering Recommendation:   Diagnose complete or partial molar pregnancy.
104.
105.
Ordering Recommendation:   Aids in the diagnosis and management of multiple myeloma and related disorders. Use to detect and quantify serum monoclonal protein.
106.
107.
108.
109.
110.
Ordering Recommendation:   May be useful when essential thrombocythemia or idiopathic myelofibrosis is suspected in JAK2 V617F-negative individuals.
111.
Ordering Recommendation:   Use to monitor previously established MPO/PR-3 antibodies or confirm an IFA c-ANCA or p-ANCA positive test result. Test does not include pANCA or cANCA testing. Refer to ANCA Reflex to Titer and MPO/PR-3 Antibodies (2002068) or ANCA-Associated Vasculites Profile (ANCA/MPO/PR-3) Reflex to ANCA Titer (2006480) for  pANCA or cANCA testing.
112.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
113.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
114.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
115.
Ordering Recommendation:   Diagnostic testing for mucolipidosis type IV.  Carrier screening for mucolipidosis type IV.
116.
Ordering Recommendation:   Diagnostic testing for mucolipidosis type IV.
117.
Ordering Recommendation:   Use to evaluate symptomatic patients for mucopolysaccharidoses (MPS). To monitor glycosaminoglycans (GAGs) in patients previously diagnosed with MPS, refer to Mucopolysaccharides, Quantitative, Urine (0081357).
118.
Ordering Recommendation:   Use to MONITOR glycosaminoglycans (GAGs) in patients previously diagnosed with a mucopolysaccharidosis (MPS). Approval by an ARUP genetic counselor or medical director required BEFORE ordering this test. To screen for MPS, refer to Mucopolysaccharides Screen - Electrophoresis & Quantitation, Urine (0081352).
119.
Ordering Recommendation:   For research use. Medical Director approval is required to order this test.
120.
Ordering Recommendation:   Use to monitor heparan sulfate (total disaccharides and nonreducing ends) for  MPS Type 1 patients who are on therapy.
121.
Ordering Recommendation:   Use to monitor heparan sulfate (total disaccharides and nonreducing ends) excretion for  MPS Type 1 patients who are on therapy.
122.
Ordering Recommendation:   Use to monitor heparan sulfate (total disaccharides and nonreducing ends) for MPS Type II patients who are on therapy.
123.
Ordering Recommendation:   Use to monitor heparan sulfate (total disaccharides and nonreducing ends) excretion for MPS Type II patients who are on therapy.
124.
Ordering Recommendation:   This is a second tier test and REQUIRES PERMISSION from  ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.
125.
Ordering Recommendation:   Diagnostic testing for multiple endocrine neoplasia type 1. Predictive testing for multiple endocrine neoplasia type 1.
126.
Ordering Recommendation:   Diagnostic testing for multiple endocrine neoplasia type 1. Predictive testing for multiple endocrine neoplasia type 1.
127.
Ordering Recommendation:   Diagnostic testing for multiple endocrine neoplasia type 2.  Predictive testing for multiple endocrine neoplasia type 2.
128.
Ordering Recommendation:   This is a second tier test and REQUIRES PERMISSION from  ARUP's Genetic Counselor (800-242-2787, x2141) before ordering. Preferred initial test is the sequencing and deletion/duplication test.
129.
Ordering Recommendation:   Preferred panel for individuals with clinical phenotype of multiple epiphyseal dysplasia.
130.
Ordering Recommendation:   Acceptable test for individuals with clinical phenotype of multiple epiphyseal dysplasia. Preferred test is Multiple Epiphyseal Dysplasia Panel, Sequencing and Deletion/Duplication, 6 Genes (2008840).
131.
Ordering Recommendation:   Aids in risk stratification of individuals with multiple myeloma. Recommended at initial diagnosis and in low-risk individuals at time of relapse.
132.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
133.
134.
135.
136.
137.
138.
139.
Ordering Recommendation:   Acceptable reflexive panel for the differential diagnosis of acquired neuromuscular junction disorders. Panel contains binding, blocking, and modulating antibodies; voltage-gated calcium and potassium channels; titin antibody; and striated muscle antibodies.
140.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
141.
Ordering Recommendation:   Secondary diagnostic testing for patients with generalized or ocular myasthenia gravis and no detectable antibodies to acetylcholine receptor (AChR).
142.
Ordering Recommendation:   Diagnostic or predictive testing for MUTYH-associated polyposis in Caucasians. For non-Caucasians, order MUTYH-Associated Polyposis (MUTYH) Sequencing (2006191).
143.
Ordering Recommendation:   Preferred diagnostic or predictive test for MUTYH-associated polyposis in Caucasians. For non-Caucasians, order MUTYH-Associated Polyposis (MUTYH) Sequencing (2006191).
144.
Ordering Recommendation:   Diagnostic or predictive testing for MUTYH-associated polyposis. Use if one or no mutations were found with 2 mutations test.
145.
Ordering Recommendation:   Facilitates diagnosis of Burkitts lymphoma (BL) and B-cell lymphoma with features intermediate between BL and diffuse large B-cell lymphoma (DLBCL). Detects all MYC rearrangements, including t(8;14), t(2;8), and t(8;22).
146.
Ordering Recommendation:   Prognostic determination in individuals with neuroblastoma or medulloblastoma.
147.
148.
149.
150.
Ordering Recommendation:   Optimize drug therapy and monitor patient adherence.
151.
Ordering Recommendation:   Identify Mycoplasma hominis in urogential specimens.
152.
153.
154.
155.
156.
157.
Ordering Recommendation:   Useful in distinguishing lymphoplasmacytic lymphoma (LPL) from other low-grade B-cell lymphoproliferative disorders which may be in the differential diagnosis.
Use when monitoring patients with LPL diagnosis and previously identified MYD88 L265P mutation.
158.
159.
160.
Ordering Recommendation:   Not recommended for the workup of suspected multiple sclerosis. Preferred test is Oligoclonal Band Profile (0080440).
161.
Ordering Recommendation:   Use in conjunction with conventional cytogenetics for diagnosis, prognosis, and monitoring of minimal residual disease (MRD) in MDS.
162.
Ordering Recommendation:   Assesses for single gene mutations, including substitutions and insertions and deletions that may have diagnostic, prognostic, and/or therapeutic significance in
Acute myeloid leukemia
Myelodysplastic syndromes
Myeloproliferative neoplasms
MDS/MPN overlap disorders such as chronic myelomonocytic leukemia
163.
Ordering Recommendation:   Detects important genomic abnormalities in acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), and MDS/MPN neoplasms that may have diagnostic, prognostic, and/or therapeutic significance:
Loss/gain of DNA
Loss of heterozygosity (LOH)
Single gene mutations (substitutions and small insertions and deletions)
164.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
165.
166.
167.
Ordering Recommendation:   Limited role in the work-up of myeloproliferative neoplasms in the setting of an otherwise optimal cytogenetic study.  Aids in exclusion of cryptic BCR-ABL1 rearrangement in chronic myelogenous leukemia and in the exclusion of a PDGFRA abnormality in cases of neoplastic eosinophilia. 
168.
169.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
170.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
171.
Ordering Recommendation:   Not a standalone test. Cardiac troponins [troponin I (0090613) or troponin T (0098803)] are the recommended tests for diagnosis and management of acute coronary syndrome.
172.
173.
Ordering Recommendation:   Refer to ARUP Immunohistochemistry Stain Offerings brochure at www.aruplab.com/ap/resources.
174.
Ordering Recommendation:   Most useful if general suspicion for inflammatory myopathy exists, including overlap syndromes.
175.
Ordering Recommendation:   Differential evaluation of patients with PM/DM and/or other connective tissue diseases or overlapping syndromes.